Who
Aine Miller
SVP, Dev & Head of Ire Office
Company insider
Files Form 4 as: SVP, Dev & Head of Ire Office, Theravance Biopharma.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Feb 2024
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —93,108 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —96,718 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —37,500 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —37,500 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —93,108 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —96,718 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $106K6,258 at $16.95 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $106K6,258 at $16.95 | filing |
| 19 Jun 2026filed 23 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $113K6,827 at $16.55 | filing |
| 20 May 2026filed 22 May 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $113K6,827 at $16.55 | filing |
| 20 Feb 2026filed 24 Feb 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $331K16,851 at $19.66 | filing |
| 20 Feb 2026filed 24 Feb 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $331K16,851 at $19.66 | filing |
| 20 Nov 2025filed 24 Nov 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $125K6,989 at $17.90 | filing |
| 20 Aug 2025filed 22 Aug 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $94K6,989 at $13.39 | filing |
| 20 May 2025filed 21 May 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $92K9,701 at $9.45 | filing |
| 19 May 2025filed 21 May 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —10,430 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 20 Feb 2025filed 24 Feb 2025 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $109K11,295 at $9.66 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.